Data from our anti-malarial Phase 2 clinical trial performed in Vietnam were published in the Journal of Experimental Medicine. These promising results show the strategy of inhibiting host erythrocyte kinases can greatly augment the efficacy of current malaria treatments.
ErythroCure is pleased to announce that Dr. Karson Putt will be joining the team as the new COO and interim CEO.
Tyrosine kinase inhibitors that halt the progression of malaria was published in the journal PLoS.
A new cellular mechanism, the inhibition of Band 3 tyrosine phosphorylation, to treat sickle cell disease was published in the British Journal of Hematology.
Mechanistic studies published in the journal Antioxidants show how SYK kinase Inhibitors synergize with the anti-malarial drug artemisinin by enhancing oxidative stress.
A phase 2 clinical trial was initiated in Vietnam to test the efficacy of adding imatinib to the current standard-of-care therapy dihydroartemisinin plus piperaquine.
Inhibitors of the tyrosine kinase SYK were shown to interfere with red blood cell membrane modifications during malaria infection. These modifications are critical for the parasite to escape from its host cell to infect new cells. This work was published in the journal Blood.
Studies detailing the inhibition of an erythrocyte tyrosine kinase with imatinib was published in PLoS. This tyrosine kinase inhibitor was shown to prevent Plasmodium falciparum, one of the parasites responsible for malaria, from escaping the red blood cell causing the trapped pathogen to die.